Hallephar SRL
Hallephar reported total assets of 610,863 € at the end of the 2025 financial year (annual accounts filed with the NBB on 10 Jul 2026).
The score of Hallephar shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity -12 % Total assets -11 %
Accounts of the company itself (not consolidated).
The full file covers 10 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Hallephar's annual accounts
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net result | 58,311 € | ||||
| Equity | 537,464 € | ||||
| Cash | 122,744 € | ||||
| EBITDA | 98,055 € | ||||
| Total assets | 610,863 € |
Filed annual accounts
- Year ended 31 Dec 2025filed on 10 Jul 2026
- Year ended 31 Dec 2024filed on 17 Jul 2025
- Year ended 31 Dec 2023filed on 18 Jul 2024
- Year ended 31 Dec 2022filed on 03 Jul 2023
- Year ended 31 Dec 2021filed on 03 Aug 2022
Hallephar's financial analysis
- Solvency88.0%sector median: 44.2%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Hallephar
Hallephar's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0426.472.178
- VAT number
- BE0426472178
- Peppol
- Registered · 0208:0426472178 · as of 10 Nov 2026
- Legal form
- SRL
- Incorporated
- 22 Nov 1984
- Registered office
- 2980 Zoersel
- Latest accounts
- 2025 · filed on 10 Jul 2026
- Activity
- Retail sale of pharmaceutical products (NACE 47730)
Hallephar (SRL) has been based in Zoersel since 1984, active in: retail sale of pharmaceutical products. For 2025, it reports a net profit of 58,311 € and equity of 537,464 €; its revenue is not published. Its solvency stands at 88.0%, above the median of its sector (44.2%).
Guide: Reading Belgian SME accounts: the five figures that count →
Companies similar to Hallephar
Companies in the same business, of comparable size and area, outside its group.
- Apotheek Karel Langen Retail sale of pharmaceutical products Bilzen-Hoeselt · balance sheet 610,859 €
- Heist-Farma Retail sale of pharmaceutical products Heist-op-den-Berg · balance sheet 610,567 €
- Pharmacie Graas Retail sale of pharmaceutical products Liège · balance sheet 610,234 €
- Blauwblomme Retail sale of pharmaceutical products Kortrijk · balance sheet 559,420 €
- Apoteek Francois Retail sale of pharmaceutical products Hechtel-Eksel · balance sheet 609,692 €
- Pharmadons Retail sale of pharmaceutical products Ixelles · balance sheet 608,875 €
- De Zeven Hoeken Retail sale of pharmaceutical products Anderlecht · balance sheet 613,685 €
- Antwerp Port Pharmacy Retail sale of pharmaceutical products Antwerp · balance sheet 607,745 €
Frequently asked questions about Hallephar
What is the revenue of Hallephar?
Hallephar files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Hallephar?
In Belgium, the VAT number is the company number prefixed with BE: BE0426472178 for Hallephar, if the company is VAT-registered. Its company number (CBE) is 0426.472.178.
Where is the registered office of Hallephar?
According to the CBE register, the registered office of Hallephar is in 2980 Zoersel.
What is the equity of Hallephar?
At the close of the 2025 financial year, the equity of Hallephar amounts to 537,464 €, a solvency of 88.0% of total assets.
Who manages Hallephar?
The register lists 1 active mandates at Hallephar. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Hallephar
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →